DB
IRD

Dmitry Balyasny’s Opus Genetics IRD Stock Holding History

Dmitry Balyasny’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7M Buy
3,087,866
+369,837
+14% +$1.73M 0.02% 950
2026
Q1 		$12.4M Hold
2,718,029
– – 0.02% 936
2025
Q4 		$5.46M Buy
+2,718,029
New +$5.52M 0.01% 1351

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Dmitry Balyasny's IRD Position: Q2 2026 in Review

Dmitry Balyasny increased its Opus Genetics (IRD) stake by 14% in Q2 2026, buying an estimated $1.73M and bringing the position to 3,087,866 shares worth $12.7M. The position accounts for 0.02% of the portfolio, ranked #950.

Dmitry Balyasny first reported a position in IRD in Q4 2025 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Dmitry Balyasny held 3,087,866 shares of Opus Genetics worth $12.7M as of Q2 2026.
  • Dmitry Balyasny bought 369,837 Opus Genetics shares in Q2 2026, an estimated $1.73M.
  • Opus Genetics made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #950 holding.
  • Dmitry Balyasny first reported a position in Opus Genetics in Q4 2025 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.